nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.08.2006 | Editorial commentary

Will innervation imaging predict ventricular arrhythmias in ischaemic cardiomyopathy?

verfasst von: Maureen M. Henneman, Frank M. Bengel, Jeroen J. Bax

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2006

Einloggen, um Zugang zu erhalten

Excerpt

With the introduction of¹²³I-metaiodobenzylguanidine (MIBG), evaluation of cardiac innervation and denervation has become feasible with SPECT. MIBG is a noradrenaline analogue, and has storage, transport and uptake characteristics similar to those of noradrenaline in sympathetic nerve endings. Uptake and retention of MIBG occur via two pathways: a neuronal pathway and a non-neuronal pathway. The neuronal pathway (uptake-1) consists of active transport sites on presynaptic nerve terminals, whereas the non-neuronal pathway (uptake-2) entails carrier-facilitated transport, mostly into other cell types. Diffusion only accounts for a small portion of the uptake and retention. In humans, the majority of uptake and retention is thought to occur via the neuronal pathway. …

Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981;22:22–31PubMed

Arimoto T, Takeishi Y, Fukui A, Tachibana H, Nozaki N, Hirono O, et al. Dynamic¹²³I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure. Ann Nucl Med 2004;18:145–150PubMed

Marini C, Giorgetti A, Gimelli A, Kusch A, Sereni N, L'abbate A, et al. Extension of myocardial necrosis differently affects MIBG retention in heart failure caused by ischaemic heart disease or by dilated cardiomyopathy. Eur J Nucl Med Mol Imaging 2005;32:682–688PubMedCrossRef

Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757–1767PubMed

Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, et al. Usefulness of meta-[¹²³I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment. Nucl Med Commun 2005;26:97–102PubMedCrossRef

Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759–766PubMedCrossRef

Merlet P, Valette H, Dubois-Rande JL, Mardon K, Pouillart F, Bourachot ML, et al. Iodine 123-labeled metaiodobenzylguanidine imaging in heart disease. J Nucl Cardiol 1994;1:S79–S85PubMedCrossRef

Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995;26:1594–1599PubMedCrossRef

Watanabe K, Takahashi T, Nakazawa M, Wahed MI, Fuse K, Tanabe N, et al. Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy. J Nucl Med 2002;43:531–535PubMed

10.

Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917–923PubMed

11.

Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation 1987;75:877–887PubMed

12.

Kammerling JJ, Green FJ, Watanabe AM, Inoue H, Barber MJ, Henry DP, et al. Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction. Circulation 1987;76:383–393PubMed

13.

Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellman HN, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988;78:1008–1019PubMed

14.

Inoue H, Zipes DP. Time course of denervation of efferent sympathetic and vagal nerves after occlusion of the coronary artery in the canine heart. Circ Res 1988;62:1111–1120PubMed

15.

Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991;325:618–624PubMedCrossRef

16.

Schwartz PJ, Randall WC, Anderson EA, Engel BT, Friedman M, Hartley LH, et al. Sudden cardiac death. Nonpharmacologic interventions. Circulation 1987;76:I215–I219PubMed

17.

Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992;85:I77–I91PubMed

18.

McGhie AI, Corbett JR, Akers MS, Kulkarni P, Sills MN, Kremers M, et al. Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction. Am J Cardiol 1991;67:236–242PubMedCrossRef

19.

Stanton MS, Tuli MM, Radtke NL, Heger JJ, Miles WM, Mock BH, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol 1989;14:1519–1526PubMedCrossRef

20.

Matsunari I, Schricke U, Bengel FM, Haase HU, Barthel P, Schmidt G, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;101:2579–2585PubMed

21.

Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation 2004;109:2685–2691PubMedCrossRef

22.

Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322–324PubMedCrossRef

23.

Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933–1940PubMedCrossRef

24.

Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002;106:2145–2161PubMedCrossRef

25.

Epstein AE. An update on implantable cardioverter—defibrillator guidelines. Curr Opin Cardiol 2004;19:23–25PubMedCrossRef

26.

Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760–3765PubMedCrossRef

27.

van der Burg AE, Bax JJ, Boersma E, Pauwels EK, van der Wall EE, Schalij MJ. Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden death. Circulation 2003;108:1954–1959PubMedCrossRef

28.

Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, Song G, et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005;45:1104–1108PubMedCrossRef

29.

Nazarian S, Bluemke DA, Lardo AC, Zviman MM, Watkins SP, Dickfeld TL, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 2005;112:2821–2825PubMedCrossRef

30.

Schäfers M, Wichter T, Lerch H, Matheja P, Kuwert T, Schäfers K, et al. Cardiac¹²³I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation. J Nucl Med 1999;40:1–5PubMed

31.

Paul M, Schäfers M, Kies P, Acil T, Schäfers K, Breithardt G, et al. Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging 2006 Apr 13 [Epub ahead of print]. DOI 10.1007/s00259-005-0061-7

32.

Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121–131PubMedCrossRef

33.

Simões MV, Barthel P, Matsunari I, Nekolla SG, Schomig A, Schwaiger M, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 2004;25:551–557PubMedCrossRef

Titel: Will innervation imaging predict ventricular arrhythmias in ischaemic cardiomyopathy?
verfasst von: Maureen M. Henneman
Frank M. Bengel
Jeroen J. Bax
Publikationsdatum: 01.08.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0166-7

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2006

Lymphatic mapping to tailor selective lymphadenectomy in cN0 tongue carcinoma: beyond the sentinel node concept

Is PET/CT necessary in paediatric oncology?

Disease activity and 18F-FDG uptake in organising pneumonia: semi-quantitative evaluation using computed tomography and positron emission tomography

Imaging of adrenocortical metastases with [11C]metomidate

Putting ‘clear’ into nuclear medicine: a decade of PET/CT development

Simplified quantification of small animal [18F]FDG PET studies using a standard arterial input function